Evidence map›Paper›PMID 33631219›Full record

ReviewVirus research2021

Protection against COVID-19 in African population: Immunology, genetics, and malaria clues for therapeutic targets.

Marcos Altable, Juan Moisés de la Serna

Open access · greenAbstract readReview
In one paragraph

Review in Virus research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Statins: Beneficial Effects in Treatment of COVID-19.Advances in experimental medicine and biology · 2023
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Marcos AltablePrivate Practice of Neurology, Neuroceuta. (Virgen de África Clinic), Ceuta, Spain. Electronic address: maraltable@gmail.com.
Juan Moisés de la SernaUNIR Research, Universidad Internacional de La Rioja, Madrid, Spain.
Hospital Virgen de la Luz · ESUniversidad Internacional De La Rioja · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a marked discrepancy between SARS-CoV-2 seroprevalence and COVID-19 cases and deaths in Africa. MAIN: SARS-CoV-2 stimulates humoral and cellular immunity systems, as well as mitogen-activated protein kinase (MAPK) and nuclear NF-kB signalling pathways, which regulate inflammatory gene expression and immune cell differentiation. The result is pro-inflammatory cytokines release, hyperinflammatory condition, and cytokine storm, which provoke severe lung alterations that can lead to multi-organ failure in COVID-19. Multiple genetic and immunologic factors may contribute to the severity of COVID-19 in African individuals when compared to the rest of the global population. In this article, the role of malaria, NF-kB and MAPK pathways, caspase-12 expression, high level of LAIR-1-containing antibodies, and differential glycophorins (GYPA/B) expression in COVID-19 are discussed.

conclusionUnderstanding pathophysiological mechanisms can help identify target points for drugs and vaccines development against COVID-19. To our knowledge, this is the first study that explores this link and proposes a biological and molecular answer to the epidemiologic discrepancy in COVID-19 in Africa.

Indexed as

AfricaCaspase 12COVID-19GlycophorinsHumansMalariaNF-kappa BReceptors, ImmunologicSARS-CoV-2Signal TransductionCaspase 12Glycophorinsleukocyte-associated immunoglobulin-like receptor 1NF-kappa BReceptors, ImmunologicAfricaCaspase 12COVID-19GlycophorinsLAIR-1MalariaMAPKNF-kBPD-1SARS-CoV-2

Identifiers

PMID33631219
PMCPMC7898966
OpenAlexW3132180801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.